Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
What Is IGF-1 LR3? Benefits, Research & Safety
A modified, highly potent analogue of insulin-like growth factor 1 with extended half-life and reduced binding protein affinity.
Also known as:
Long R3 IGF-1
Long Arginine 3-IGF-1
LR3-IGF-1
UK summary: Not a licensed UK medicine. A potent IGF-1 analogue with extended half-life and reduced binding-protein affinity. Prohibited at all times under WADA S2 (IGF-1 and analogues). Theoretical cancer-promotion concerns are not fully resolved.
Quick Facts
Category
Hormonal & Endocrine
Half-Life
20-30 hours (compared to ~15 minutes for native IGF-1)
UK Status
Not licensed for any indication. Research compound only. Prohibited in sport.
EU Status
Not approved for human use in any EU member state.
Overview
IGF-1 LR3 (Long Arginine 3 Insulin-like Growth Factor 1) is a synthetic, modified analogue of naturally occurring IGF-1. It consists of 83 amino acids compared to the 70 of native IGF-1, with specific modifications that dramatically alter its pharmacological properties.
The "Long" refers to a 13-amino acid extension at the N-terminus, while "R3" indicates an arginine substitution at position 3. These modifications reduce binding to IGF binding proteins (IGFBPs), resulting in significantly increased bioavailability and a much longer half-life compared to native IGF-1.
IGF-1 is one of the primary mediators of growth hormone's anabolic effects, playing crucial roles in growth, development, and tissue repair throughout life. By reducing IGFBP binding, IGF-1 LR3 has much greater potency than native IGF-1 on a per-molecule basis.
This peptide has attracted significant interest in research settings for studying IGF-1 physiology and in the bodybuilding community for its potent anabolic effects. However, it carries significant safety concerns related to its potency and potential for serious adverse effects.
IGF-1 LR3 is not approved for human use and is classified as a research compound. It is prohibited in sport by WADA.
Evidence standards summary
IGF-1 LR3 — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
DAnimal/cell evidence onlyOverall grade against our evidence grading methodology.
Not a licensed UK medicine. A potent IGF-1 analogue with extended half-life and reduced binding-protein affinity. Prohibited at all times under WADA S2 (IGF-1 and analogues). Theoretical cancer-promotion concerns are not fully resolved.
02Human evidence grade
ETheoretical / insufficientStrength of evidence from published human trials.
03Preclinical evidence grade
CLimited human evidenceAnimal-model and in-vitro evidence quality.
04Regulatory status
- UK: Not licensed for any indication. Research compound only. Prohibited in sport.
- EU: Not approved for human use in any EU member state.
- Notes: IGF-1 LR3 is not approved anywhere for human therapeutic use. Native recombinant IGF-1 (mecasermin/Increlex) is approved for specific growth disorders but is different from IGF-1 LR3. WADA prohibits IGF-1 LR3 in sport.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Adds muscle mass faster than any natural training stimulus.
- Safe to inject site-specifically for localised muscle growth.
- Reverses sarcopenia in healthy adults.
- Undetectable in standard drug tests.
07Common internet claims
- Marketed as the strongest legal anabolic peptide.
- Recommended in bodybuilding stacks alongside HGH, testosterone, and insulin.
- Promoted for use in-between bulk and cut cycles for muscle preservation.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Builds muscle without affecting blood sugar” | D | No | High | IGF-1 analogues can affect glucose metabolism; muscle-building claims in healthy adults are not supported by human trial data. |
| “Safe long-term” | E | No | High | Long-term IGF-1 elevation has theoretical cancer-promotion concerns that are not fully resolved. |
| “Allowed in untested sports” | E | No | High | Prohibited at all times under WADA S2; strict-liability applies regardless of testing schedule. |
09Safety uncertainty score
Very high
Effectively no human safety data; safety claims are extrapolations from animal work or anecdote.
10Known adverse signals
- Hypoglycaemia (IGF-1 binds insulin receptor at high doses).
- Carpal tunnel symptoms, joint pain, organ growth at sustained exposure.
- Theoretical promotion of pre-existing cancers — IGF-1 is mitogenic.
- Cardiac and renal hypertrophy reported with chronic IGF-1 elevation.
11Drug-interaction uncertainty
High
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
WADA: Prohibited in sportWADA strict-liability framing applies.
13UK legal position
UK: Unlicensed (UK)
Not licensed for any indication. Research compound only. Prohibited in sport.
14EU legal position
Not approved for human use in any EU member state.
15What this page cannot tell you
- Whether a UK-purchased vial contains IGF-1 LR3 at the labelled concentration.
- How it interacts with insulin, testosterone, or growth hormone in a typical stack.
- What the cancer risk is from sustained supraphysiological IGF-1 in young healthy adults.
- Whether it triggers WADA detection — assume yes, prohibition is strict-liability.
16Last reviewed
17Citation quality score
DAnimal/cell evidence onlyQuality of the sources we cite, graded against the evidence grading methodology.
18Research gaps
- No published Phase 3 trials for any indication in healthy adults.
- Long-term oncologic surveillance data does not exist.
- Combination-stack safety entirely uncharacterised.
- Detection-window data from WADA is intentionally restricted.
19Safer alternatives / established care pathways
- Structured progressive-overload resistance training with adequate protein intake.
- GP review for testosterone or growth hormone deficiency if clinically suspected.
- Licensed mecasermin (Increlex) only when there is genuine severe primary IGF-1 deficiency under a specialist.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is IGF-1 LR3 a licensed UK medicine?
- What are the theoretical cancer-related risks of chronic IGF-1 elevation?
- If I'm tested in sport, what is my WADA exposure?
- What licensed alternatives exist for the underlying goal?
Discovery & History
IGF-1 (Insulin-like Growth Factor 1) was first characterised in the 1970s and recognised as a key mediator of growth hormone's biological effects. Understanding of its physiology led to therapeutic development of recombinant human IGF-1 (mecasermin) for certain growth disorders.
The development of IGF-1 LR3 arose from efforts to create more potent and longer-lasting analogues for research purposes. Scientists discovered that native IGF-1's biological activity is largely regulated by IGF binding proteins (IGFBPs), which sequester the hormone and limit its free, active concentration.
By engineering specific modifications—the N-terminal extension and the arginine substitution—researchers created a variant with dramatically reduced IGFBP binding. This resulted in much higher free IGF-1 activity and a significantly extended half-life.
IGF-1 LR3 became a valuable research tool for studying IGF-1 physiology independent of binding protein regulation. It allowed researchers to examine the effects of sustained, high IGF-1 receptor activation.
The peptide never progressed to clinical development due to safety concerns related to its potency. However, it became available through research chemical suppliers and gained popularity in bodybuilding communities, leading to concerns about unregulated use.
Mechanism of Action
IGF-1 LR3 exerts its effects through potent activation of the IGF-1 receptor (IGF-1R), with reduced regulation by binding proteins:
**Reduced IGFBP Binding**
The structural modifications dramatically reduce affinity for IGF binding proteins:
- Native IGF-1 is >90% bound to IGFBPs in circulation
- IGF-1 LR3 has much lower IGFBP affinity
- Results in much higher free, biologically active peptide
- Contributes to both increased potency and longer half-life
**IGF-1 Receptor Activation**
IGF-1 LR3 maintains full ability to activate the IGF-1 receptor:
- Triggers intracellular signaling cascades (PI3K/Akt, MAPK pathways)
- Promotes protein synthesis and inhibits protein breakdown
- Stimulates cell proliferation and differentiation
- Inhibits apoptosis (cell death)
**Anabolic Effects**
The downstream effects include:
- Increased muscle protein synthesis
- Enhanced nitrogen retention
- Stimulation of satellite cell activation (muscle stem cells)
- Potential effects on fat metabolism
- Support of tissue repair and regeneration
**Glucose Metabolism**
IGF-1 has insulin-like effects on glucose metabolism:
- Can lower blood glucose
- Potential for hypoglycaemia, especially at higher doses
- Cross-reactivity with insulin receptor at high concentrations
Researched Benefits
Based on preclinical and clinical research findings:
- 1Potent stimulation of muscle protein synthesis
- 2Enhanced nitrogen retention and anabolic environment
- 3Extended half-life compared to native IGF-1
- 4Research tool for studying IGF-1 physiology
- 5Potential tissue repair and regeneration effects
- 6Possible hyperplasia (new muscle cell formation) in addition to hypertrophy
Claim vs Evidence
How popular claims about IGF-1 LR3 stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Builds muscle without affecting blood sugar” | D | No | High | IGF-1 analogues can affect glucose metabolism; muscle-building claims in healthy adults are not supported by human trial data. |
| “Safe long-term” | E | No | High | Long-term IGF-1 elevation has theoretical cancer-promotion concerns that are not fully resolved. |
| “Allowed in untested sports” | E | No | High | Prohibited at all times under WADA S2; strict-liability applies regardless of testing schedule. |
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | 20-100 mcg per day (from research literature; wide variation) |
| Frequency | Once daily or divided doses |
| Duration | 4-6 weeks cycles commonly cited in research literature |
| Notes | ⚠️ IGF-1 LR3 is not approved for human use and carries significant safety risks. These protocols are extrapolated from research settings and anecdotal reports. Hypoglycemia is a serious risk. Medical supervision is essential. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection
- Intramuscular injection (some research protocols)
| Half-Life | Stability |
|---|---|
| 20-30 hours (compared to ~15 minutes for native IGF-1) | Requires careful handling; lyophilised powder stored at -20°C; reconstituted solution refrigerated |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Hypoglycaemia (low blood sugar) - potentially severe
- Joint pain and swelling
- Jaw pain or growth
- Headaches
- Water retention
- Injection site reactions
Rare Risks & Concerns
- Severe hypoglycaemia (medical emergency)
- Acceleration of tumour growth (potent mitogen)
- Organ growth (heart, intestines)
- Acromegaly-like effects with chronic use
- Cardiomyopathy with prolonged use
- Unknown long-term effects
Contraindications
- Active or history of cancer (potent growth factor)
- Diabetes or hypoglycaemic tendency
- Pregnancy and breastfeeding
- Children and adolescents (except under specialist care)
- Cardiovascular disease
- Any condition where cell proliferation is concerning
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed for any indication. Research compound only. Prohibited in sport.
🇪🇺 European Union
Not approved for human use in any EU member state.
IGF-1 LR3 is not approved anywhere for human therapeutic use. Native recombinant IGF-1 (mecasermin/Increlex) is approved for specific growth disorders but is different from IGF-1 LR3. WADA prohibits IGF-1 LR3 in sport.
Clinical Studies Summary
IGF-1 LR3 in Cell Culture and Animal Research
Extensive use in laboratory research examining IGF-1 physiology and signaling pathways.
Endocrinology and cell biology journalsView on PubMed
IGF-1 and Muscle Physiology
Research on the role of IGF-1 in muscle development, hypertrophy, and repair.
Physiology and sports medicine journalsView on PubMed
Looking for IGF-1 LR3?
Source research-grade IGF-1 LR3 from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about IGF-1 LR3
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is IGF-1 LR3 a licensed UK medicine?
- What are the theoretical cancer-related risks of chronic IGF-1 elevation?
- If I'm tested in sport, what is my WADA exposure?
- What licensed alternatives exist for the underlying goal?
UK regulatory & safety context
Related Research Guides
Related Peptides
HGH Fragment 176-191
A fragment of human growth hormone corresponding to amino acids 176-191, researched specifically for its fat-metabolising properties.
Learn moreCJC-1295
A synthetic growth hormone-releasing hormone analogue designed for extended half-life and sustained growth hormone secretion.
Learn moreIpamorelin
A selective growth hormone-releasing peptide known for its favourable side effect profile, stimulating GH release without significantly affecting cortisol or prolactin.
Learn morePEG-MGF
A PEGylated version of mechano growth factor with extended half-life, researched for muscle repair and hypertrophy.
Learn more